SIM
AZN icon

Sentry Investment Management’s AstraZeneca AZN Stock Holding History

Sentry Investment Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-16,500
Closed -$857K – 524
2013
Q3 		$857K Hold
16,500
– – 0.05% 271
2013
Q2 		$780K Buy
+16,500
New +$840K 0.05% 196

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
MAA
Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
PFM
PacWest Financial Management Phoenix, Arizona $169M AUM 8.84% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Sentry Investment Management's AZN Position: Q4 2013 in Review

Sentry Investment Management sold out of AstraZeneca (AZN) in Q4 2013, closing a stake of 16,500 shares — an estimated $857K sold.

Sentry Investment Management first reported a position in AZN in Q2 2013 and held it in 2 quarters. The position peaked at $857K in Q3 2013. 380 funds tracked by Wall St. Rank hold AZN as of Q4 2013.

  • Sentry Investment Management reported no remaining AstraZeneca position as of Q4 2013 after selling out during the quarter.
  • Sentry Investment Management sold 16,500 AstraZeneca shares in Q4 2013, an estimated $857K.
  • Sentry Investment Management first reported a position in AstraZeneca in Q2 2013 and held it in 2 quarters.
  • Sentry Investment Management's AstraZeneca position peaked at $857K in Q3 2013.
  • 380 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2013.

Based on Sentry Investment Management's 13F filing for Q4 2013, filed 10 Feb 2014.